Savara Inc.

NasdaqGS SVRA

Savara Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -81.47 M

Savara Inc. Free Cash Flow is USD -81.47 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -83.54% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Savara Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -44.39 M, a -25.69% change year over year.
Savara Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -35.31 M, a 17.95% change year over year.
Savara Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -43.04 M, a -5.54% change year over year.
Savara Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -40.78 M, a 11.09% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: SVRA

Savara Inc.

CEO	Mr. Matthew Pauls J.D., M.B.A.
IPO Date	April 28, 2017
Location	United States
Headquarters	Building III
Employees	37
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Key trends

Past 5 years